Clinical trials: Patients With Locally Advanced Rectal Cancer
Metastatic Colorectal Cancer, Gastric Cancer
Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer
This is an open-label, multicenter study to assess the safety, tolerability, pharmacokinetics, and antitumor activity of vactosertib in combination with pembrolizumab in patients with metastatic or locally advanced colorectal or…
- Conditions
- Metastatic Colorectal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT03724851
- Testing
- TEW-7197
- Where
- 5 sites in South Korea
- Volunteers
- 120 people
- Sponsor
- MedPacto, Inc.
Advanced Malignant Solid Neoplasm, Clinical Stage III Gastroesophageal Junction Adenocarcinoma
Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer
This phase I trial investigates the side effects and best dose of talazoparib when given together with trifluridine/tipiracil for the treatment of patients with colorectal or gastroesophageal cancer that has spread to nearby…
- Conditions
- Advanced Malignant Solid Neoplasm, Clinical Stage III Gastroesophageal Junction Adenocarcinoma, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT04511039
- Testing
- Trifluridine and Tipiracil Hydrochloride, Talazoparib Tosylate
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Roswell Park Cancer Institute
Locally Advanced Rectal Carcinoma
Comparison of the Clinical Response of Total Neoadjuvant Treatment of Two Methods of Long-term or Short-term Chemoradiotherapy in Rectal Cancer
Rectal cancer is one of the most prevalent malignancies in the world, and its prevalence is rising. In more advanced cases neoadjuvant therapy is advised before to surgery, and radiotherapy is one of its cornerstones.
- Trial name
- TEHRAN (NCT05920928)
- Testing
- Short course radiotherapy with concurrent capecitabine(825mg/m2), Long course radiotherapy with concurrent capecitabine(825mg/m2)
- Volunteers
- 114 people
- Sponsor
- Tehran University of Medical Sciences
Colorectal Cancer
Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine As Conversion Therapy of Locally Advanced Colorectal Cancer
Neoadjuvant chemotherapy has gained acceptance in treating locally advanced breast cancer, esophageal cancer, gastric cancer, and rectal cancer.
- Trial name
- NCT06405139
- Testing
- Nanoliposomal Irinotecan, Oxaliplatin plus Capecitabine
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Rectal Cancer, Liver Metastases
Preoperative CRT With or Without Induction Chemotherapy for Rectal Cancer With Liver Metastases
To investigate the feasibility of preoperative chemoradiation with oxaliplatin plus capecitabine, with or without prior induction chemotherapy in patients with locally advanced or marginally resectable rectal cancer with…
- Trial name
- NCT01643070
- Testing
- Capecitabine, Oxaliplatin, Radiotherapy
- Where
- South Korea
- Volunteers
- 38 people
- Sponsor
- Asan Medical Center
Locally Advanced Rectal Cancer, Older People
Efficacy and Safety of Conventional Neoadjuvant Therapy Versus Total Neoadjuvant Therapy in Older Patients With Locally Advanced Rectal Cancer
The SHAPERS study is a multicentre, open-label, randomised, pragmatic clinical trial, comparing standard-of-care neoadjuvant treatment options for older (i.e., ≥70 years) subjects with high-risk stage II and stage III rectal…
- Trial name
- SHAPERS (NCT06052332)
- Testing
- Short course radiotherapy, Adjuvant chemotherapy (optional), Total mesorectal excision
- Where
- 19 sites in Belgium
- Volunteers
- 230 people
- Sponsor
- Jules Bordet Institute
Locally Advanced Rectal Cancer
Dose-escalation Trial of Preoperative Radiotherapy and Concurrent Chemotherapy in Locally Advanced Rectal Cancer
The aim of this study is to evaluate the increase of radiation dose administered in patients diagnosed with locally advanced rectal cancer in terms of ypRC with tolerable toxicity, using IMRT (concomitant boost technique).
- Trial name
- NCT02964468
- Testing
- 3DCRT treatment (sequential boost), Dose Escalation Intensity Modulated Radiotherapy treatment
- Where
- 9 sites in Spain
- Volunteers
- 525 people
- Sponsor
- Grupo de Investigación Clínica en Oncología Radioterapia
Adenocarcinoma of Rectum
Capecitabine Plus Simvastatin in Locally Advanced Rectal Cancer Patients
Statins are widely used as lipid-lowering agents to lower cardiovascular risk with a favorable safety profile. In our recent in vitro study, the addition of simvastatin to chemoradiotherapy with 5-FU showed synergistic anticancer…
- Trial name
- NCT02161822
- Testing
- simvastatin
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Samsung Medical Center
Rectal Cancer, Self Efficacy
An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer
The aim of this study is to evaluate the feasibility and acceptability of conducting a randomized trial of a brief psychoeducational intervention versus enhanced usual care for patients with locally advanced rectal cancer who are…
- Trial name
- PATHWAYS (NCT05914766)
- Testing
- PATHWAYS, Enhanced usual care
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Massachusetts General Hospital
Unresectable Colorectal Cancer, Colorectal Cancer (Locally Advanced or Metastatic)
FMT Combined With Standard First-Line Therapy in Initially Unresectable Colorectal Cancer
This clinical trial evaluates the efficacy and safety of adding fecal microbiota transplantation (FMT) to first-line standard of care for patients with initially unresectable colorectal cancer (CRC).
- Trial name
- NCT07509398
- Testing
- Standard First-Line Therapy, FMT Combined with Standard First-Line Therapy
- Volunteers
- 220 people
- Sponsor
- Shanghai 10th People's Hospital
Cancer, Tumor, Solid
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of subcutaneously administered JK08 in patients with unresectable locally, advanced…
- Conditions
- Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer
- Trial name
- NCT05620134
- Testing
- JK08, Pembrolizumab, Lenvatinib Pill
- Where
- 11 sites in Belgium, Spain
- Volunteers
- 263 people
- Sponsor
- Salubris Biotherapeutics Inc
Rectal Cancer Patients
Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.
This study is a multicenter, prospective, randomized, double-arm, Phase II clinical trial designed to evaluate the efficacy of short-term radiotherapy combined with Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as…
- Trial name
- NCT06911684
- Testing
- lparomlimab and Tuvonralimab Injection and regorafenib and CPAOX and short-course radiotherapy
- Where
- China
- Volunteers
- 88 people
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer, Cervical Cancer
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous participant-derived engeneered T cells are engineered to express a T cell receptor that recognizes cancer-associated antigens…
- Conditions
- Head and Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma, Melanoma
- Trial name
- NCT05973487
- Testing
- TSC-204-A0201, TSC-204-C0702, TSC-200-A0201
- Where
- 21 sites in United States
- Volunteers
- 840 people
- Sponsor
- TScan Therapeutics, Inc.
Colorectal Cancer
Oxaliplatin With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies such as gefitinib may interfere with the growth of the tumor cells and slow the growth…
- Trial name
- NCT00026299
- Testing
- ZD1839, oxaliplatin
- Where
- 12 sites in United States
- Volunteers
- 14 people
- Sponsor
- University of Chicago
Colorectal Adenocarcinoma, RAS Wild Type
Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
This randomized phase II trial studies how well irinotecan and cetuximab with or without bevacizumab work in treating patients with RAS wild-type colorectal cancer that has spread to other places in the body (locally…
- Conditions
- Colorectal Adenocarcinoma, RAS Wild Type, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7
- Trial name
- NCT02292758
- Testing
- Bevacizumab, Cetuximab, Irinotecan
- Where
- 13 sites in United States
- Volunteers
- 36 people
- Sponsor
- Academic and Community Cancer Research United
Rectal Neoplasms, Drug Therapy
Totally Neoadjuvant FOLFOXIRI + Short-course Radiation + XELOX in Patients With Locally Advanced Rectal Cancer
To evaluate the efficacy and safety of totally neoadjuvant FOLFOXIRI chemotherapy (irinotecan, oxaliplatin and fluorouracil) followed by short-course radiation therapy and XELOX chemotherapy in the patients with locally advanced…
- Conditions
- Rectal Neoplasms, Drug Therapy, Radiation
- Trial name
- NCT03484221
- Testing
- FOLFOXIRI, Short-Course Radiation Therapy(5Gy*5), XELOX
- Where
- China
- Volunteers
- 30 people
- Sponsor
- China Medical University, China
Melanoma, Non-Small Cell Lung Cancer
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
This is a Phase 1a/1b, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, immune response, and pharmacokinetics of autogene cevumeran (RO7198457) as a single agent and in…
- Conditions
- Melanoma, Non-Small Cell Lung Cancer, Bladder Cancer, Colorectal Cancer
- Trial name
- NCT03289962
- Testing
- Autogene cevumeran, Atezolizumab
- Where
- 33 sites in United States, Belgium and 6 more
- Volunteers
- 273 people
- Sponsor
- Genentech, Inc.
Metastatic Colorectal Cancer
Assessment of Clinical Practice Administration of Chemotherapy and Anti-angiogenic Agent (Bevacizumab) in Colorectal Cancer
Investigators propose to assess, retrospectively (from 1/7/2009) and prospectively (up to 31/12/2013,) the safety and tolerability profile (number of participants with adverse events) of standard chemotherapy and anti-angiogenic…
- Trial name
- NCT01811108
- Where
- 6 sites in Greece
- Volunteers
- 670 people
- Sponsor
- Hellenic Oncology Research Group
Rectal Cancer
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
The purpose of this research study is to evaluate epacadostat when given with routine radiation therapy and chemotherapy (capecitabine and oxaliplatin) to treat rectal cancer before routine surgery is performed to remove the…
- Trial name
- NCT03516708
- Testing
- Epacadostat, Short-course radiation therapy, CAPOX chemotherapy
- Where
- 4 sites in United States
- Volunteers
- 49 people
- Sponsor
- Washington University School of Medicine
Locally Advanced Rectal Cancer
Observational Study on Rectal Cancer to Verify if Response After Chemo-radiotherapy Can be Predicted With a Particular Blood Test.
Research project for patients with locally advanced rectal cancer in which biological material and health-related personal data are collected.
- Trial name
- LiBReCa (NCT03699410)
- Testing
- Neoadjuvant radiotherapy, Neoadjuvant chemotherapy, Radical surgery
- Where
- 2 sites in Switzerland
- Volunteers
- 25 people
- Sponsor
- Dimitri Christoforidis